These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [The prospects for improving chemical cholera vaccines]. Markov EIu; Maramovich AS; Golubinskiĭ EP; Urbanovich LIa Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):91-6. PubMed ID: 9783412 [No Abstract] [Full Text] [Related]
7. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform. Liao J; Gibson JA; Pickering BS; Watnick PI mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145 [TBL] [Abstract][Full Text] [Related]
8. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638. Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342 [TBL] [Abstract][Full Text] [Related]
9. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. Jertborn M; Svennerholm AM; Holmgren J J Infect Dis; 1988 Feb; 157(2):374-7. PubMed ID: 3335813 [No Abstract] [Full Text] [Related]
10. Molecular design of cholera vaccines. Manning PA Vaccine; 1992; 10(14):1015-21. PubMed ID: 1361701 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542 [TBL] [Abstract][Full Text] [Related]
12. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect. Wasserman SS; Kotloff KL; Losonsky GA; Levine MM Am J Epidemiol; 1993 Dec; 138(11):988-93. PubMed ID: 8256784 [TBL] [Abstract][Full Text] [Related]
13. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives]. Carrada-Bravo T Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108 [TBL] [Abstract][Full Text] [Related]
14. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase. Stewart-Tull DE; Lucas C; Bleakley CR Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770 [TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of antibacterial and antitoxin immunities in experimental cholera. Srivastava R; Sinha VB; Srivastava BS Indian J Med Res; 1979 Sep; 70():369-73. PubMed ID: 535945 [No Abstract] [Full Text] [Related]
16. Current status of cholera and rise of novel mucosal vaccine. Yamamoto T Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702 [TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a thyA mutant derived from cholera vaccine candidate IEM101. Yu F; Qi G; Liu Y; Gao S; Kan B Mol Biotechnol; 2005 Mar; 29(3):191-6. PubMed ID: 15767696 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera. Bondre VP; Sinha VB; Srivastava BS FEMS Immunol Med Microbiol; 1997 Dec; 19(4):323-9. PubMed ID: 9537758 [TBL] [Abstract][Full Text] [Related]
19. [Suppressive effects of IgE antibody formation of orally administered living and killed Vibrio cholerae cells in mice]. Komagata Y Kansenshogaku Zasshi; 1984 Apr; 58(4):318-26. PubMed ID: 6434656 [No Abstract] [Full Text] [Related]
20. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Jertborn M; Nordström I; Kilander A; Czerkinsky C; Holmgren J Infect Immun; 2001 Jun; 69(6):4125-8. PubMed ID: 11349086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]